G1 Therapeutics Chief Commercial Officer John Demaree receives $7.5M in 2018
G1 Therapeutics reports 2018 executive compensation
By ExecPay News
Published: April 24, 2020
G1 Therapeutics reported fiscal year 2018 executive compensation information on April 24, 2020.
In 2018, six executives at G1 Therapeutics received on average a compensation package of $3.2M, a 121% increase compared to previous year.
Average pay of disclosed executives at G1 Therapeutics
John Demaree, Chief Commercial Officer, received $7.5M in total. 95% of Demaree's compensation, or $7.1M, was in option awards. Demaree also received $131K in bonus, $186K in salary, as well as $42K in other compensation.
James Stillman Hanson, General Counsel, received a compensation package of $4.9M. 95% of the compensation package, or $4.7M, was in option awards.
Terry L. Murdock, Chief Operating Officer, earned $2.7M in 2018, a 139% increase compared to previous year.
Mark A. Velleca, Chief Executive Officer, received $1.9M in 2018, which increases by 159% compared to 2017.
Rajesh K. Malik, Chief Medical Officer, earned $1.3M in 2018, a 153% increase compared to previous year.
Barclay Buck A. Phillips, Chief Financial Officer, received $715K in 2018, which decreases by 79% compared to 2017.
Related executives
Rajesh Malik
G1 Therapeutics
Chief Medical Officer
Mark Velleca
G1 Therapeutics
Chief Executive Officer
Barclay Phillips
G1 Therapeutics
Chief Financial Officer
Terry Murdock
G1 Therapeutics
Chief Operating Officer
John Demaree
G1 Therapeutics
Chief Commercial Officer
James Hanson
G1 Therapeutics
General Counsel
You may also like
Source: SEC filing on April 24, 2020.